SCHEDULE: Millennium Management Discloses 5.3% Stake in Beta Bionics

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.3% beneficial ownership stake in Beta Bionics, Inc. common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. Common Stock.
• This ownership represents 5.3% of the total outstanding shares of Beta Bionics, Inc.
• The filing was made under Rule 13d-1(c), indicating a passive investment purpose, not for changing or influencing control of the issuer.
• The reporting persons share both voting and dispositive power over all 2,286,728 shares.
• The event requiring this filing occurred on September 15, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a prominent institutional investor like Millennium Management is generally viewed positively as it indicates institutional interest and potential validation of the company's prospects. However, it does not provide operational or financial performance details.

Positives

• A significant institutional investor, Millennium Management, has taken a 5.3% passive stake in Beta Bionics, which can signal confidence in the company's long-term prospects.
• The investment is explicitly stated as not being for the purpose of changing or influencing control, suggesting a belief in the current management and strategic direction.

Risks

• The filing itself does not introduce new risks but reflects the inherent market risks associated with holding common stock.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Beta Bionics or the reporting persons regarding the company's future performance.

Industry Context

The disclosure of a significant stake by a major hedge fund like Millennium Management in Beta Bionics, a company focused on automated insulin delivery systems, highlights continued institutional interest in the medical technology and biotech sectors. Such investments can sometimes precede increased market attention or further institutional accumulation in the industry.

Stakeholder Impact

• Shareholders may perceive increased confidence in Beta Bionics due to the backing of a major institutional investor, potentially leading to positive market sentiment.
• The company's management may view this as a validation of their strategy and operations, given the passive nature of the investment.

Next Steps

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander may adjust their beneficial ownership in Beta Bionics, Inc. in the future, which would require subsequent filings.

Key Dates

Recommendation

The filing indicates a significant passive stake by a reputable institutional investor, Millennium Management, which can be a positive signal for Beta Bionics. However, a Schedule 13G primarily discloses ownership and does not provide operational or financial performance details to warrant a stronger recommendation. Investors should consider this institutional interest alongside other fundamental analysis.

Keywords

Beta Bionics, Millennium Management, Israel A. Englander, Schedule 13G, beneficial ownership, institutional investment, common stock, passive stake